Revopsis Therapeutics, INC.
Last verified 2026-05-08. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $1.9Mattributed |
|---|---|
| Latest round | strategic, $1.9M, 2024-01-01attributed |
| Founded | unknown |
| Headquarters | Springfield, USA |
| Industry | unknown |
| Stage | series-b+ |
| Website | revopsis.com |
TRANSFORMATIONAL NEXT GENERATION HIGH AFFINITY TRISPECIFIC FAB PROTEIN TO ADDRESS UNMET NEEDS IN OPHTHALMOLOGY - PROJECT
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-01-01 | strategic | $1.9M | undisclosed |
Detected tech stack
Cloudflare, PHP 8.2.30, Google Analytics, Google Tag Manager, GSAP 3.4.2, DoubleClick Floodlight, WordPress, SWC, MySQL, jquery 3.3.1
Provenance
| Fact | Status | Basis |
|---|---|---|
| Strategic, $1.9M | attributed | sbir named as publisher. No document URL on file. |
| Total raised $1.9M | attributed | sbir named as publisher. No document URL on file. |
| Company existence | self-reported | revopsis.com, read 2026-05-08 |
| Description | self-reported | revopsis.com, read 2026-05-08 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.